A Phase I, Dose-Finding Study of Sorafenib in Combination with Gemcitabine and Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) Study

PURPOSE: Sorafenib, an oral inhibitor of B-raf, VEGFR2, and PDGFR2-beta, acts against pancreatic cancer in preclinical models. Due to the radio-sensitization activity of both sorafenib and gemcitabine, we designed a multicenter, phase I trial to evaluate the safety profile and the recommended dose o...

Descripción completa

Detalles Bibliográficos
Autores principales: Aparicio, Jorge, García-Mora, Carmen, Martín, Marta, Petriz, Ma Lourdes, Feliu, Jaime, Sánchez-Santos, Ma Elena, Ayuso, Juan Ramón, Fuster, David, Conill, Carlos, Maurel, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886976/
https://www.ncbi.nlm.nih.gov/pubmed/24416138
http://dx.doi.org/10.1371/journal.pone.0082209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886976/
https://www.ncbi.nlm.nih.gov/pubmed/24416138
http://dx.doi.org/10.1371/journal.pone.0082209

Ejemplares similares